Trending News

Blog Post


EU starts real-time review of AstraZeneca COVID-19 antibody cocktail By Reuters 

© Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski

(Reuters) -Europe’s drug regulator said on Thursday it had started a real-time review of the antibody-based COVID-19 therapy developed by AstraZeneca (NASDAQ:), roughly a week after the Anglo-Swedish drugmaker sought emergency approval from U.S. authorities.

The decision to begin the assessment by the human medicines committee of the European Medicines Agency (EMA) was based on early results from clinical studies, the regulator said in a statement, without specifying when a conclusion was expected.

The medicine, the first protective shot other than vaccines against COVID-19, has proven to work in the non-infected and was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.

“EMA will evaluate more data on the quality, safety and effectiveness of the medicine as they become available,” the watchdog said, adding that the rolling review would continue until AstraZeneca submits a formal application for approval.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Related posts

Leave a Reply

Required fields are marked *